Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines : World Health Organization consultations, October 2021—March 2022
Q3
- Autores:
-
Prudden, Holly J.
Achilles, Sharon L.
Schocken, Celina
Broutet, Nathalie
Canfell, Karen
Akaba, Hiroki
Basu, Partha
Bhatla, Neerja
Chirenje, Z. Mike
Delany-Moretlwe, Sinead
Denny, Lynette
Gamage, Deepa G.
Herrero, Rolando
Hutubessy, Raymond
Villa, Luisa Lina
Murillo, Raul
Schiller, John T.
Stanley, Margaret
Temmerman, Marleen
Zhao, Fanghui
Ogilvie, Gina
Kaslow, David C.
Dull, Peter
Gottlieb, Sami L.
Therapeutic HPV Vaccine PPC Expert Consultation Group
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2022
- Institución:
- Pontificia Universidad Javeriana
- Repositorio:
- Repositorio Universidad Javeriana
- Idioma:
- eng
- OAI Identifier:
- oai:repository.javeriana.edu.co:10554/63858
- Acceso en línea:
- https://www.sciencedirect.com/science/article/pii/S0264410X22009999?via%3Dihub
http://hdl.handle.net/10554/63858
https://doi.org/10.1016/j.vaccine.2022.08.020
- Palabra clave:
- Cervical cancer
HPV
Therapeutic HPV vaccine
Preferred product characteristics
- Rights
- License
- Atribución-NoComercial 4.0 Internacional
| id |
JAVERIANA2_c2fe0eecfd5547aaa9876f5f09465015 |
|---|---|
| oai_identifier_str |
oai:repository.javeriana.edu.co:10554/63858 |
| network_acronym_str |
JAVERIANA2 |
| network_name_str |
Repositorio Universidad Javeriana |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines : World Health Organization consultations, October 2021—March 2022 |
| title |
Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines : World Health Organization consultations, October 2021—March 2022 |
| spellingShingle |
Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines : World Health Organization consultations, October 2021—March 2022 Cervical cancer HPV Therapeutic HPV vaccine Preferred product characteristics |
| title_short |
Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines : World Health Organization consultations, October 2021—March 2022 |
| title_full |
Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines : World Health Organization consultations, October 2021—March 2022 |
| title_fullStr |
Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines : World Health Organization consultations, October 2021—March 2022 |
| title_full_unstemmed |
Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines : World Health Organization consultations, October 2021—March 2022 |
| title_sort |
Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines : World Health Organization consultations, October 2021—March 2022 |
| dc.creator.fl_str_mv |
Prudden, Holly J. Achilles, Sharon L. Schocken, Celina Broutet, Nathalie Canfell, Karen Akaba, Hiroki Basu, Partha Bhatla, Neerja Chirenje, Z. Mike Delany-Moretlwe, Sinead Denny, Lynette Gamage, Deepa G. Herrero, Rolando Hutubessy, Raymond Villa, Luisa Lina Murillo, Raul Schiller, John T. Stanley, Margaret Temmerman, Marleen Zhao, Fanghui Ogilvie, Gina Kaslow, David C. Dull, Peter Gottlieb, Sami L. Therapeutic HPV Vaccine PPC Expert Consultation Group |
| dc.contributor.author.none.fl_str_mv |
Prudden, Holly J. Achilles, Sharon L. Schocken, Celina Broutet, Nathalie Canfell, Karen Akaba, Hiroki Basu, Partha Bhatla, Neerja Chirenje, Z. Mike Delany-Moretlwe, Sinead Denny, Lynette Gamage, Deepa G. Herrero, Rolando Hutubessy, Raymond Villa, Luisa Lina Murillo, Raul Schiller, John T. Stanley, Margaret Temmerman, Marleen Zhao, Fanghui Ogilvie, Gina Kaslow, David C. Dull, Peter Gottlieb, Sami L. Therapeutic HPV Vaccine PPC Expert Consultation Group |
| dc.contributor.corporatename.spa.fl_str_mv |
Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Medicina Interna. Grupo de Oncología. Centro Javeriano de Oncología |
| dc.contributor.javerianateacher.none.fl_str_mv |
Murillo, Raul |
| dc.subject.keyword.spa.fl_str_mv |
Cervical cancer HPV Therapeutic HPV vaccine Preferred product characteristics |
| topic |
Cervical cancer HPV Therapeutic HPV vaccine Preferred product characteristics |
| description |
Q3 |
| publishDate |
2022 |
| dc.date.created.none.fl_str_mv |
2022-08-22 |
| dc.date.accessioned.none.fl_str_mv |
2023-03-17T19:27:51Z |
| dc.date.available.none.fl_str_mv |
2023-03-17T19:27:51Z |
| dc.type.local.spa.fl_str_mv |
Artículo de revista |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
| format |
http://purl.org/coar/resource_type/c_6501 |
| dc.identifier.spa.fl_str_mv |
https://www.sciencedirect.com/science/article/pii/S0264410X22009999?via%3Dihub |
| dc.identifier.issn.spa.fl_str_mv |
0264-410X / 1873-2518 (Electrónico) |
| dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/10554/63858 |
| dc.identifier.doi.spa.fl_str_mv |
https://doi.org/10.1016/j.vaccine.2022.08.020 |
| dc.identifier.instname.spa.fl_str_mv |
instname:Pontificia Universidad Javeriana |
| dc.identifier.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional - Pontificia Universidad Javeriana |
| dc.identifier.repourl.spa.fl_str_mv |
repourl:https://repository.javeriana.edu.co |
| url |
https://www.sciencedirect.com/science/article/pii/S0264410X22009999?via%3Dihub http://hdl.handle.net/10554/63858 https://doi.org/10.1016/j.vaccine.2022.08.020 |
| identifier_str_mv |
0264-410X / 1873-2518 (Electrónico) instname:Pontificia Universidad Javeriana reponame:Repositorio Institucional - Pontificia Universidad Javeriana repourl:https://repository.javeriana.edu.co |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.citationstartpage.spa.fl_str_mv |
5843 |
| dc.relation.citationendpage.spa.fl_str_mv |
5855 |
| dc.relation.ispartofjournal.spa.fl_str_mv |
Vaccine |
| dc.relation.citationvolume.spa.fl_str_mv |
40 |
| dc.relation.citationissue.spa.fl_str_mv |
41 |
| dc.rights.licence.*.fl_str_mv |
Atribución-NoComercial 4.0 Internacional |
| dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by-nc/4.0/ |
| dc.rights.coar.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| rights_invalid_str_mv |
Atribución-NoComercial 4.0 Internacional http://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_abf2 |
| dc.format.spa.fl_str_mv |
PDF |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.coverage.temporal.none.fl_str_mv |
2021-2022 |
| institution |
Pontificia Universidad Javeriana |
| bitstream.url.fl_str_mv |
http://repository.javeriana.edu.co/bitstream/10554/63858/1/Understanding%20the%20public%20health%20value%20and%20defining%20preferred%20product%20characteristics%20for%20therapeutic%20human%20papillomavirus%20%28HPV%29%20vaccines%20World%20Health%20Organization%20consultations%2c%20October%202021%e2%80%94March%202022.pdf http://repository.javeriana.edu.co/bitstream/10554/63858/2/license.txt http://repository.javeriana.edu.co/bitstream/10554/63858/3/Understanding%20the%20public%20health%20value%20and%20defining%20preferred%20product%20characteristics%20for%20therapeutic%20human%20papillomavirus%20%28HPV%29%20vaccines%20World%20Health%20Organization%20consultations%2c%20October%202021%e2%80%94March%202022.pdf.jpg |
| bitstream.checksum.fl_str_mv |
c781539d70b262c30013f1c96f023cb4 2070d280cc89439d983d9eee1b17df53 0647d2da72271579eac4f720b953a76a |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional - Pontificia Universidad Javeriana |
| repository.mail.fl_str_mv |
repositorio@javeriana.edu.co |
| _version_ |
1811670651988082688 |
| spelling |
Atribución-NoComercial 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_abf2Prudden, Holly J.Achilles, Sharon L.Schocken, CelinaBroutet, NathalieCanfell, KarenAkaba, HirokiBasu, ParthaBhatla, NeerjaChirenje, Z. MikeDelany-Moretlwe, SineadDenny, LynetteGamage, Deepa G.Herrero, RolandoHutubessy, RaymondVilla, Luisa LinaMurillo, RaulSchiller, John T.Stanley, MargaretTemmerman, MarleenZhao, FanghuiOgilvie, GinaKaslow, David C.Dull, PeterGottlieb, Sami L.Therapeutic HPV Vaccine PPC Expert Consultation GroupPontificia Universidad Javeriana. Facultad de Medicina. Departamento de Medicina Interna. Grupo de Oncología. Centro Javeriano de OncologíaMurillo, Raul2021-20222023-03-17T19:27:51Z2023-03-17T19:27:51Z2022-08-22https://www.sciencedirect.com/science/article/pii/S0264410X22009999?via%3Dihub0264-410X / 1873-2518 (Electrónico)http://hdl.handle.net/10554/63858https://doi.org/10.1016/j.vaccine.2022.08.020instname:Pontificia Universidad Javerianareponame:Repositorio Institucional - Pontificia Universidad Javerianarepourl:https://repository.javeriana.edu.coPDFapplication/pdfengUnderstanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines : World Health Organization consultations, October 2021—March 2022Artículo de revistahttp://purl.org/coar/resource_type/c_6501Q3Q1Mujeres con cáncer de cuello uterinoThe World Health Organization (WHO) global strategy to eliminate cervical cancer (CxCa) could result in >62 million lives saved by 2120 if strategy targets are reached and maintained: 90% of adolescent girls receiving prophylactic human papillomavirus (HPV) vaccine, 70% of women receiving twice-lifetime cervical cancer screening, and 90% of cervical pre-cancer lesions and invasive CxCa treated. However, the cost and complexity of CxCa screening and treatment approaches has hampered scale-up, particularly in low- and middle-income countries (LMICs), and new approaches are needed. Therapeutic HPV vaccines (TxV), which could clear persistent high-risk HPV infection and/or cause regression of pre-cancerous lesions, are in early clinical development and might offer one such approach. During October 2021 to March 2022, WHO, in collaboration with the Bill and Melinda Gates Foundation, convened a series of global expert consultations to lay the groundwork for understanding the potential value of TxV in the context of current CxCa prevention efforts and for defining WHO preferred product characteristics (PPCs) for TxV. WHO PPCs describe preferences for vaccine attributes that would help optimize vaccine value and use in meeting the global public health need. This paper reports on the main discussion points and findings from the expert consultations. Experts identified several ways in which TxV might address challenges in current CxCa prevention programmes, but emphasized that the potential value of TxV will depend on their degree of efficacy and how quickly they can be developed and implemented relative to ongoing scale-up of existing interventions. Consultation participants also discussed potential use-cases for TxV, important PPC considerations (e.g., vaccine indications, target populations, and delivery strategies), and critical modelling needs for predicting TxV impact and cost-effectiveness.https://orcid.org/0000-0001-7187-9946Revista Internacional - IndexadaA1NoCervical cancerHPVTherapeutic HPV vaccinePreferred product characteristics58435855Vaccine4041ORIGINALUnderstanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines World Health Organization consultations, October 2021—March 2022.pdfUnderstanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines World Health Organization consultations, October 2021—March 2022.pdfArtículoapplication/pdf1856385http://repository.javeriana.edu.co/bitstream/10554/63858/1/Understanding%20the%20public%20health%20value%20and%20defining%20preferred%20product%20characteristics%20for%20therapeutic%20human%20papillomavirus%20%28HPV%29%20vaccines%20World%20Health%20Organization%20consultations%2c%20October%202021%e2%80%94March%202022.pdfc781539d70b262c30013f1c96f023cb4MD51open accessLICENSElicense.txtlicense.txttext/plain; charset=utf-82603http://repository.javeriana.edu.co/bitstream/10554/63858/2/license.txt2070d280cc89439d983d9eee1b17df53MD52open accessTHUMBNAILUnderstanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines World Health Organization consultations, October 2021—March 2022.pdf.jpgUnderstanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines World Health Organization consultations, October 2021—March 2022.pdf.jpgIM Thumbnailimage/jpeg9077http://repository.javeriana.edu.co/bitstream/10554/63858/3/Understanding%20the%20public%20health%20value%20and%20defining%20preferred%20product%20characteristics%20for%20therapeutic%20human%20papillomavirus%20%28HPV%29%20vaccines%20World%20Health%20Organization%20consultations%2c%20October%202021%e2%80%94March%202022.pdf.jpg0647d2da72271579eac4f720b953a76aMD53open access10554/63858oai:repository.javeriana.edu.co:10554/638582023-03-18 03:03:52.59Repositorio Institucional - Pontificia Universidad Javerianarepositorio@javeriana.edu.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 |